TW200616621A - Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals - Google Patents
Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animalsInfo
- Publication number
- TW200616621A TW200616621A TW094125600A TW94125600A TW200616621A TW 200616621 A TW200616621 A TW 200616621A TW 094125600 A TW094125600 A TW 094125600A TW 94125600 A TW94125600 A TW 94125600A TW 200616621 A TW200616621 A TW 200616621A
- Authority
- TW
- Taiwan
- Prior art keywords
- alk
- animals
- modulate
- inhibitors
- lean tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59235904P | 2004-07-29 | 2004-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200616621A true TW200616621A (en) | 2006-06-01 |
Family
ID=35595039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094125600A TW200616621A (en) | 2004-07-29 | 2005-07-28 | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060194845A1 (zh) |
EP (1) | EP1771171A1 (zh) |
JP (1) | JP2008506787A (zh) |
CN (1) | CN101031294A (zh) |
AR (1) | AR050187A1 (zh) |
AU (1) | AU2005280496B2 (zh) |
BR (1) | BRPI0513914A (zh) |
CA (1) | CA2576734C (zh) |
MX (1) | MX2007001118A (zh) |
NO (1) | NO20071113L (zh) |
PE (1) | PE20060729A1 (zh) |
TW (1) | TW200616621A (zh) |
WO (1) | WO2006025988A1 (zh) |
ZA (1) | ZA200700681B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
WO2008136739A1 (en) * | 2007-05-04 | 2008-11-13 | Jana Pickova | Compound feed for aquaculture |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
CN101678107A (zh) | 2007-08-03 | 2010-03-24 | 萨米特公开有限公司 | 用于治疗杜兴型肌营养不良的药物组合物 |
WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
CN101684457B (zh) * | 2009-07-27 | 2013-01-09 | 中国科学院广州生物医药与健康研究院 | I型转化生长因子受体抑制剂在产生诱导多能干细胞中的应用及其方法 |
EP2694653A2 (en) * | 2011-04-05 | 2014-02-12 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Compounds and methods for altering activin receptor-like kinase signalling |
WO2013137832A1 (en) * | 2012-03-16 | 2013-09-19 | Nanyang Technological University | Myostatin inhibitors |
PT2880053T (pt) | 2012-08-01 | 2020-05-22 | Ikaika Therapeutics Llc | Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 |
US10265372B2 (en) | 2014-08-12 | 2019-04-23 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
JP2022511112A (ja) | 2018-12-11 | 2022-01-28 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Alk5阻害剤としてのナフチリジンおよびキノリン誘導体 |
US20220143136A1 (en) | 2018-12-21 | 2022-05-12 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
JP2023502662A (ja) | 2019-11-22 | 2023-01-25 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Alk5阻害剤としての置換1,5-ナフチリジンまたはキノリン |
US20230414711A1 (en) * | 2020-11-13 | 2023-12-28 | The Jackson Laboratory | Therapeutics targeting transforming growth factor beta family signaling |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
CN100567322C (zh) * | 1999-01-21 | 2009-12-09 | 梅塔莫菲克斯公司 | 抑制生长分化因子活性的多肽及表达该多肽的细胞 |
ATE231143T1 (de) * | 1999-04-09 | 2003-02-15 | Smithkline Beecham Corp | Triarylimidazole |
GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
-
2005
- 2005-07-27 EP EP05810799A patent/EP1771171A1/en not_active Withdrawn
- 2005-07-27 BR BRPI0513914-7A patent/BRPI0513914A/pt not_active IP Right Cessation
- 2005-07-27 AR ARP050103119A patent/AR050187A1/es not_active Application Discontinuation
- 2005-07-27 PE PE2005000882A patent/PE20060729A1/es not_active Application Discontinuation
- 2005-07-27 JP JP2007522848A patent/JP2008506787A/ja active Pending
- 2005-07-27 CA CA2576734A patent/CA2576734C/en not_active Expired - Fee Related
- 2005-07-27 US US11/190,453 patent/US20060194845A1/en not_active Abandoned
- 2005-07-27 MX MX2007001118A patent/MX2007001118A/es not_active Application Discontinuation
- 2005-07-27 CN CNA2005800331272A patent/CN101031294A/zh active Pending
- 2005-07-27 AU AU2005280496A patent/AU2005280496B2/en not_active Ceased
- 2005-07-27 WO PCT/US2005/026607 patent/WO2006025988A1/en active Application Filing
- 2005-07-28 TW TW094125600A patent/TW200616621A/zh unknown
-
2007
- 2007-01-24 ZA ZA200700681A patent/ZA200700681B/en unknown
- 2007-02-27 NO NO20071113A patent/NO20071113L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008506787A (ja) | 2008-03-06 |
MX2007001118A (es) | 2007-03-15 |
EP1771171A1 (en) | 2007-04-11 |
WO2006025988A1 (en) | 2006-03-09 |
BRPI0513914A (pt) | 2008-05-20 |
US20060194845A1 (en) | 2006-08-31 |
CN101031294A (zh) | 2007-09-05 |
AU2005280496B2 (en) | 2009-10-08 |
AR050187A1 (es) | 2006-10-04 |
ZA200700681B (en) | 2008-07-30 |
NO20071113L (no) | 2007-02-27 |
CA2576734A1 (en) | 2006-03-09 |
AU2005280496A1 (en) | 2006-03-09 |
CA2576734C (en) | 2010-03-16 |
PE20060729A1 (es) | 2006-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200616621A (en) | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | |
PH12013500913A1 (en) | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | |
UA96777C2 (ru) | Фенилпропионамидные соединения и их применение как опиоидных агонистов | |
ATE550031T1 (de) | Zusammensetzungen und verfahren für die lipomodellierung | |
EP2177224A3 (en) | Agents for preventing and treating disorders involving modulation of the RyR receptors | |
ECSP067080A (es) | DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA | |
TNSN08396A1 (en) | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual | |
ATE293691T1 (de) | Myostatin genpromoter und inhibierung dessen aktivierung | |
DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
UA99540C2 (ru) | Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение | |
DE602007011904D1 (de) | Piperazinyl-oxoalkyl-tetrahydroisochinoline und verwandte analoga | |
BRPI0414794A (pt) | oxadiazolidinadionas substituìdas | |
ATE545441T1 (de) | Verfahren und vorrichtungen zur minimal invasiven abgabe von zellhaltigen fliessfähigen zusammensetzungen | |
CY1109031T1 (el) | Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου | |
BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos | |
ATE478661T1 (de) | Verfahren zur reduzierung der angiogenese | |
MX2009013205A (es) | Derivados de pirazoloquinolina urea terapeuticos. | |
MX2009013202A (es) | Derivados terapeuticos de pirazoloquinolina. | |
MX2009013197A (es) | Derivados terapeuticos de pirazolonaftiridina. | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
WO2007104933A8 (en) | Chemical compounds | |
UY30557A1 (es) | Tratamiento y prevencion de la fibrosis intestinal | |
BRPI0800744A2 (pt) | composiÇço de inibiÇço de infecÇço por salmonella para pinto e mÉtodo de inibiÇço de infecÇço por salmonella em pintos | |
BR0314821A (pt) | Derivado de piperidina, composição farmacêutica, uso do derivado de piperidina, e, método para tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo |